Does reduced renal urate excretion–driven hyperuricemia promote endothelial oxidative stress and vascular inflammation?

Systemic accumulation of uric acid, or hyperuricemia, serves as a critical pathophysiological bridge linking renal clearance dynamics to downstream cardiovascular and vascular pathology.

Renal excretion and systemic accumulation

• Reduced renal excretion is the primary driver of hyperuricemia, accounting for approximately 70% to 90% of all clinical cases.
• This excretory deficit is regulated in the proximal tubule, where the apical transporter URAT1 and basolateral transporter GLUT9 coordinate to reabsorb 90% to 95% of filtered urate back into systemic circulation.
• Clinical differentiation of this phenotype is established using the fractional excretion of uric acid (FEUA); a FEUA value below 5% to 5.5% confirms a renal underexcretion state.

Endothelial oxidative stress and vascular inflammation

• Intracellular uric acid acts as a potent pro-oxidant in endothelial cells by rapidly activating membrane-bound NADPH oxidase (NOX), which triggers a surge in reactive oxygen species (ROS) and causes mitochondrial dysfunction.
• This oxidative state directly impairs endothelial nitric oxide synthase (eNOS) activity, depleting nitric oxide (NO) bioavailability and inducing endothelial dysfunction.
• Cellular ROS accumulation serves as an upstream trigger that activates redox-sensitive inflammatory pathways, including NF-κB, the NLRP3 inflammasome, and the HMGB1/RAGE axis.
• Activation of these pathways drives the transcription of key pro-inflammatory cytokines (such as TNF-alpha and IL-6) and vascular adhesion molecules (ICAM-1 and VCAM-1), accelerating chronic vascular inflammation.

Bottom line

• Elevated uric acid is predominantly a consequence of reduced renal clearance—driven by URAT1 and GLUT9 transport kinetics—and directly promotes vascular disease by inducing NADPH oxidase-mediated endothelial oxidative stress and triggering downstream NF-κB and NLRP3 inflammatory cascades.